#Taipei #USA #Foresee Pharmaceuticals #Primevera Therapeutics #MMP-12 Inhibitors

Foresee Pharmaceuticals Expands Reach through New Partnership with Primevera Therapeutics

Foresee Pharmaceuticals, a prominent player in the biopharmaceutical sector, has officially announced a global licensing agreement with Primevera Therapeutics for its MMP-12 inhibitor programs. This strategic move, undertaken by Foresee Pharmaceuticals USA Inc., the company’s fully-owned U.S. subsidiary, is expected to solidify its position within the industry while setting the stage for future growth.

During the 2025 Extraordinary General Shareholders' Meeting, held for the purpose of approving this agreement, Foresee revealed that this partnership encompasses multiple projects, including FP-025, FP-020, and other next-generation MMP-12 inhibitors that are currently in the drug discovery pipeline. The licensing agreement will see Foresee receiving an upfront payment of $10 million, alongside potential milestone payments reaching up to an impressive $584.5 million, plus tiered royalties once the new drugs enter the market.

One of the most significant aspects of this agreement is that Foresee will maintain a 19% equity stake in Primevera, ensuring that it can benefit from the value generated by this new collaboration. This license is anticipated to greatly enhance the working capital and shareholder equity of Foresee while simultaneously reducing R&D expenditures, thereby contributing to the company's financial stability and paving the way for profitability in the near to mid-term.

With Foresee at a pivotal point in its growth trajectory, this partnership enables capabilities for a more concentrated focus on its innovative Stabilized Injectable Formulation (SIF) portfolio. In particular, the firm aims to bolster revenue streams through the commercialization of CAMCEVI, its long-acting injectable product that has garnered success in treating central precocious puberty (CPP). Following a successful pivotal Phase 3 study, the company is expecting to submit a New Drug Application (NDA) for this formulation in 2026.

In terms of development plans, Primevera will spearhead the costs associated with the MMP-12 inhibitors. The program developments include:
- FP-020: Aiming for an Investigational New Drug (IND) application for Phase II clinical trials focused on asthma treatment, with submissions to the U.S. FDA anticipated in early 2026.
- FP-025: Targeting future Phase II clinical trials related to rare disease applications.

Reflecting on this transformative chapter for Foresee, Dr. Ben Chien, PhD, Chairman and CEO, expressed his excitement about the partnership. He highlighted the unwavering commitment Foresee has demonstrated in its decade-long journey of developing MMP-12 inhibitors, a commitment that has established the company as a global leader in this arena. This collaboration with Primevera paves the way for the realization of Foresee's objectives in achieving a streamlined operational focus while continuing to nurture its path toward sustained profitability.

In addition to these developments, Foresee's robust product portfolio underscores its dedication to addressing unmet medical needs. Amongst its achievements are regulatory approvals for CAMCEVI in various regions, including the United States, Canada, and the European Union, aimed at treating advanced prostate cancer. As the firm continues to innovate, its pipeline projects look promising, especially those targeting rare and significant health issues that remain unmet.

As Foresee navigates through this partnership with Primevera, stakeholders and investors will keenly observe the unfolding outcomes of this strategic agreement, recognizing its potential to significantly boost Foresee's presence and influence in the biopharmaceutical landscape. With focused operations on its stable injectable formulations and targeted product developments, Foresee anticipates a future filled with growth and innovation, contributing to specialized healthcare solutions worldwide.